The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Cyclo Therapeutics, Inc(NASDAQ:CYTH) 
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related ...
Website: https://www.cyclotherapeutics.com/
Founded: 1990
CEO: Scott Fine
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Share this website to your friends
Cyclo Therapeutics Days Payable Outstanding ttm (DPO)
Cyclo Therapeutics Days Receivable Outstanding ttm (DSO)
Cyclo Therapeutics Days Inventory Outstanding ttm (DIO)
Cyclo Therapeutics Op Cashflow Per Share ttm
Cyclo Therapeutics Free Cashflow Per Share ttm
Cyclo Therapeutics Cash Per Share ttm
Cyclo Therapeutics P/S ratio ttm
Cyclo Therapeutics (GAAP) P/E ratio ttm
Cyclo Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.